Inotuzumab ozogamicin (2) – Besponsa®
Acute lymphoblastic B-cell leukaemia, relapsed/refractory, following allogeneic haematopoietic stem cell transplantation or following a very high-risk relapse or following ≥ 2 prior treatments, CD22+, paediatric patients aged ≥ 1 year
Characteristics
| Start date | 01.06.2026 |
|---|---|
| Resolution | 19.11.2026 – active procedure |
| INN | Inotuzumab ozogamicin |
| Brand name | Besponsa® |
| Pharm. company | Pfizer Pharma GmbH |
| G-BA Procedure ID | D-1323 |
| Therapeutic area | Oncological diseases Orphan |
| Reason for procedure | New therapeutic indication |
Associated procedures
<< List of all resolutions